Analysis of risk factors for patients with cesarean scar pregnancy treated with methotrexate combined with suction curettage.
Arch Gynecol Obstet
; 308(3): 913-918, 2023 09.
Article
en En
| MEDLINE
| ID: mdl-37131042
ABSTRACT
PURPOSE:
To analyze the predictive value of clinical and ultrasound parameters for treatment failure after administration of methotrexate (MTX) in combination with suction curettage (SC) in treatment of cesarean scar pregnancy (CSP) in the early first trimester.METHODS:
In this retrospective cohort study, electronic medical records of patients diagnosed with CSP and initially treated between 2015 and 2022 with MTX combined with SC were reviewed and outcome data were collected.RESULTS:
127 patients met inclusion criteria. 25 (19.69%) required additional treatment. Logistic regression analysis indicated that factors independently associated with the need for additional treatment included progesterone level > 25 mIU/mL (OR 1.97; 95% CI 0.98-2.87, P = 0.039), abundant blood flow (OR 5.19; 95% CI 2.44-16.31, P = 0.011), gestational sac size > 3 cm (OR 2.54; 95% CI 1.12-6.87, P = 0.029), and the myometrial thickness between the bladder and gestational sac < 2.5 mm (OR 3.48; 95% CI 1.91-6.98, P = 0.015).CONCLUSIONS:
Our study identified several factors which increase the need for additional treatment following the initial treatment of CSP with MTX and SC. Alternative therapy should be considered if these factors are present.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Embarazo Ectópico
/
Metotrexato
Tipo de estudio:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Pregnancy
Idioma:
En
Revista:
Arch Gynecol Obstet
Asunto de la revista:
GINECOLOGIA
/
OBSTETRICIA
Año:
2023
Tipo del documento:
Article
País de afiliación:
China